Immunohistochemistry features and molecular pathology of appendiceal neoplasms

References

• Shaib WL, Assi R, Shamseddine A, et al. Appendiceal mucinous neoplasms: diagnosis and management. Oncologist. 2017;22(9):1107–1116.
   PubMed Web of Science ®Google Scholar
• Benedix F, Reimer A, Gastinger I, et al.; Study Group Colon/Rectum Carcinoma Primary Tumor. Primary appendiceal carcinoma-epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36(8):763–771.
   PubMed Web of Science ®Google Scholar
• Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum. 1998;41(1):75–80.
   PubMed Web of Science ®Google Scholar
• Bucher P, Mathe Z, Demirag A, et al. Appendix tumors in the era of laparoscopic appendectomy. Surg Endosc. 2004;18(7):1063–1066.
   PubMed Web of Science ®Google Scholar
• McCusker ME, Cote TR, Clegg LX, et al. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer. 2002;94(12):3307–3312.
   PubMed Web of Science ®Google Scholar
• Marmor S, Portschy PR, Tuttle TM, et al. The rise in appendiceal cancer incidence: 2000–2009. J Gastrointest Surg. 2015;19(4):743–750.
   PubMed Web of Science ®Google Scholar
• Mikaeel RR, Young JP, Hardingham JE, et al. Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. Expert Rev Gastroenterol Hepatol. 2020. DOI:https://doi.org/10.1080/17474124.2021.1832467
   Google Scholar
• Gündoğar Ö, Kımıloğlu E, Komut N, et al. Evaluation of appendiceal mucinous neoplasms with a new classification system and literature review. Turk J Gastroenterol. 2018;29(5):533–542.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Digestive System Tumours. WHO Classification of Tumours. 5th ed. Vol. 1. 2019. WHO Classification of Tumours Editorial Board. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019
   Google Scholar
• Liu X, Mody K, de Abreu FB, et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem. 2014;60(7):1004–1011.
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Fraser-Hill M, Auer R, et al. Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer Imaging. 2013;13:14–25.
   PubMed Web of Science ®Google Scholar
• Valasek MA, Pai RK. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv Anatom Pathol. 2018;25(1):38–60.
   PubMed Web of Science ®Google Scholar
• Carr NJ, Cecil TD, Mohamed F, et al.; Peritoneal Surface Oncology Group International. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14–26.
   PubMed Web of Science ®Google Scholar
• Carr NJ, Bibeau F, Bradley RF, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–858.
   PubMed Web of Science ®Google Scholar
• Smeenk R, Van Velthuysen M, Verwaal V, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.
   PubMed Web of Science ®Google Scholar
• Pai RK, Beck AH, Norton JA, et al. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33(10):1425–1439.
   PubMed Web of Science ®Google Scholar
• Aho AJ, Heinonen R, Lauren P. Benign and malignant mucocele of the appendix. Histological types and prognosis. Acta Chir Scand. 1973;139(4):392–400.
   PubMedGoogle Scholar
• Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei. Surg Gynecol Obstet. 1992;175(5):401–404.
   PubMedGoogle Scholar
• Michael JO, Compton CC, Raghav K. Appendiceal mucinous lesions. 2019. Available from: https://www.uptodate.com/contents/appendiceal-mucinous-lesions Overman MJ, Compton CC, Raghav K, Lambert LA. Appendiceal mucinous lesions. UpToDate. Waltham MA: UpToDate Inc. 2020. Available from: https://www.uptodate.com/contents/appendiceal-mucinous-lesions
   Google Scholar
• Bartlett DJ, Thacker PG Jr, Grotz TE, et al. Mucinous appendiceal neoplasms: classification, imaging, and HIPEC. Abdom Radiol (NY). 2019;44(5):1686–1702.
   PubMed Web of Science ®Google Scholar
• Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor‐like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer. 1995;75(3):757–768.
   PubMed Web of Science ®Google Scholar
• Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–1103.
   PubMed Web of Science ®Google Scholar
• Yantiss RK, Goodarzi M, Zhou XK, et al. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol. 2009;33(4):572–582.
   PubMed Web of Science ®Google Scholar
• Shin JH, Bae JH, Lee A, et al. CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 2010;40(3):208–213.
   PubMed Web of Science ®Google Scholar
• Strickland S, Parra-Herran C. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours. Histopathology. 2016;68(7):977–987.
   PubMed Web of Science ®Google Scholar
• Schmoeckel E, Kirchner T, Mayr D. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): a series of seven cases. Pathol Res Pract. 2018;214(3):426–430.
   PubMed Web of Science ®Google Scholar
• Vang R, Gown AM, Barry TS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19(11):1421–1428.
   PubMed Web of Science ®Google Scholar
• Moh M, Krings G, Ates D, et al. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016;40(3):419–432.
   PubMed Web of Science ®Google Scholar
• Hara K, Saito T, Hayashi T, et al. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathol Res Pract. 2015;211(9):657–664.
   PubMed Web of Science ®Google Scholar
• Noguchi R, Yano H, Gohda Y, et al. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med. 2015;4(12):1809–1816.
   PubMed Web of Science ®Google Scholar
• Nishikawa G, Sekine S, Ogawa R, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer. 2013;108(4):951–958.
   PubMed Web of Science ®Google Scholar
• Lee SE, Lee EH, Park H, et al. The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. Hum Pathol. 2012;43(8):1234–1242.
   PubMed Web of Science ®Google Scholar
• Yamada M, Sekine S, Ogawa R, et al. Frequent activating GNAS mutations in villous adenoma of the colorectum. J Pathol. 2012;228(1):113–118.
   PubMed Web of Science ®Google Scholar
• Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340(6236):692–696.
   PubMed Web of Science ®Google Scholar
• Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92ra66.
   PubMed Web of Science ®Google Scholar
• Zhu X, Salhab M, Tomaszewicz K, et al. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms. Hum Pathol. 2019;85:260–269.
   PubMed Web of Science ®Google Scholar
• Borazanci E, Millis SZ, Kimbrough J, et al. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol. 2017;8(1):164–172.
   PubMed Web of Science ®Google Scholar
• Zauber P, Berman E, Marotta S, et al. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scand J Gastroenterol. 2011;46(7–8):869–874.
   PubMed Web of Science ®Google Scholar
• Tsai JH, Yang CY, Yuan RH, et al. Correlation of molecular and morphological features of appendiceal epithelial neoplasms. Histopathology. 2019;75(4):468–477.
   PubMed Web of Science ®Google Scholar
• Schell MJ, Yang M, Teer JK, et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun. 2016;7:11743.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
   PubMed Web of Science ®Google Scholar
• Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.
   PubMed Web of Science ®Google Scholar
• LaFramboise WA, Pai RK, Petrosko P, et al. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants. Mod Pathol. 2019;32(8):1197–1209.
   PubMed Web of Science ®Google Scholar
• Giannakis M, Hodis E, Mu XJ, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264–1266.
   PubMed Web of Science ®Google Scholar
• Ryland GL, Hunter SM, Doyle MA, et al.; Australian Ovarian Cancer Study Group. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol. 2013;229(3):469–476.
   PubMed Web of Science ®Google Scholar
• Lai C, Sun W, Wang X, et al. RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer. Pathol Res Pract. 2019;215(8):152453.
   PubMed Web of Science ®Google Scholar
• Liao X, Vavinskaya V, Sun K, et al. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology. 2020;76(3):461–469.
   PubMed Web of Science ®Google Scholar
• Leeming A, Worrall D, Arends MJ. The molecular pathology of appendiceal neoplasms. Am J Surg Pathol. 2019;24(3):94–97.
   Google Scholar
• Nummela P, Saarinen L, Thiel A, et al. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 2015;136(5):E282–E289.
   PubMed Web of Science ®Google Scholar
• Pai RK, Hartman DJ, Gonzalo DH, et al. Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. Hum Pathol. 2014;45(2):227–235.
   PubMed Web of Science ®Google Scholar
• Carr NJ, Mahajan H, Tan KL, et al. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol. 2009;62(6):516–518.
   PubMed Web of Science ®Google Scholar
• Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27(11):1521–1539.
   PubMed Web of Science ®Google Scholar
• Shetty S, Natarajan B, Thomas P, et al. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg. 2013;79(11):1171–1176.
   PubMed Web of Science ®Google Scholar
• Sirintrapun SJ, Blackham AU, Russell G, et al. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol. 2014;45(8):1597–1604.
   PubMed Web of Science ®Google Scholar
• Muller D. [Appendiceal neoplasm resulting from a malignant transformation of a villous adenoma. Chirurg. 1980;51(9):609–610.
   PubMed Web of Science ®Google Scholar
• Kabbani W, Houlihan PS, Luthra R, et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol. 2002;15(6):599–605.
   PubMed Web of Science ®Google Scholar
• Li Z, Roth R, Rock JB, et al. Dual immunostain with SATB2 and CK20 differentiates appendiceal mucinous neoplasms from ovarian mucinous neoplasms. Am J Clin Pathol. 2017;147(5):484–491.
   PubMed Web of Science ®Google Scholar
• Elias KM, Labidi-Galy SI, Vitonis AF, et al. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecol Oncol. 2014;132(2):328–333.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16(5):403–410.
   PubMed Web of Science ®Google Scholar
• van Eeden S, Offerhaus GJ, Hart AA, et al. Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology. 2007;51(6):763–773.
   PubMed Web of Science ®Google Scholar
• Alsaad KO, Serra S, Schmitt A, et al. Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol. 2007;18(1):16–22.
   PubMed Web of Science ®Google Scholar
• Macak J, Nemejcova K, Dvorackova J. Are goblet cell carcinoids a group of heterogeneous tumors? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161(3):281–285.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Long H, Wang W, et al. Clinicopathological features and immunoexpression profiles of goblet cell carcinoid and typical carcinoid of the appendix. Pathol Oncol Res. 2011;17(1):127–132.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Zhang Q, Zhang Y, et al. MUC1 predicts colorectal cancer metastasis: a systematic review and meta-analysis of case controlled studies. PLoS One. 2015;10(9):e0138049.
   PubMed Web of Science ®Google Scholar
• Davison JM, Hartman DA, Singhi AD, et al. Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms. Am J Surg Pathol. 2014;38(5):583–592.
   PubMed Web of Science ®Google Scholar
• Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Nat Acad Sci U S A. 2008;105(11):4283–4288.
   PubMed Web of Science ®Google Scholar
• Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999;18(20):3098–3103.
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol. 2000;24(11):1544–1548.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Kim BH, Lee HS, et al. Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors. Mod Pathol. 2009;22(8):1102–1112.
   PubMed Web of Science ®Google Scholar
• Yajima N, Wada R, Yamagishi S, et al. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum Pathol. 2005;36(11):1217–1225.
   PubMed Web of Science ®Google Scholar
• Chu PG, Chung L, Weiss LM, et al. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol. 2011;35(12):1830–1836.
   PubMed Web of Science ®Google Scholar
• Russo A, Bazan V, Agnese V, et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005;16(suppl_4):iv44–iv49.
   PubMedGoogle Scholar
• Suehiro Y, Wong CW, Chirieac LR, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 2008;14(9):2560–2569.
   PubMed Web of Science ®Google Scholar
• Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698.
   PubMed Web of Science ®Google Scholar
• Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta. 2005;1756(2):115–125.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Cortes U, Ferru A, et al. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2013;72(2):397–403.
   PubMed Web of Science ®Google Scholar
• Raghav KP, Shetty AV, Kazmi SM, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18(12):1270–1277.
   PubMed Web of Science ®Google Scholar
• Stein A, Strong E, Clark Gamblin T, et al. Molecular and genetic markers in appendiceal mucinous tumors: a systematic review. Ann Surg Oncol. 2020;27(1):85–97.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Perrone F, Mennitto A, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016;27(11):2097–2103.
   PubMed Web of Science ®Google Scholar
• Zhao M, Mishra L, Deng C-X. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–123.
   PubMed Web of Science ®Google Scholar
• Ang CS-P, Shen JP, Hardy-Abeloos CJ, et al. Genomic landscape of appendiceal neoplasms. J Clin Oncol Precision Oncol. 2018;2:1–18.
   PubMed Web of Science ®Google Scholar
• Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun. 2003;306(4):799–804.
   PubMed Web of Science ®Google Scholar
• Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol. 2000;156(1):37–43.
   PubMed Web of Science ®Google Scholar
• Alakus H, Babicky ML, Ghosh P, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014;6(5):43.
   PubMedGoogle Scholar
• Tokunaga R, Xiu J, Johnston C, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin Cancer Res. 2019;25(10):3096–3103.
   PubMed Web of Science ®Google Scholar
• Luo ZJ, Zhang XF, Rapp U, et al. Identification of the 14.3.3 zeta domains important for self-association and Raf binding. J Biol Chem. 1995;270(40):23681–23687.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313–319.
   PubMed Web of Science ®Google Scholar
• Bond CE, Whitehall VLJ. How the BRAF V600E mutation defines a distinct subgroup of colorectal cancer: molecular and clinical implications. Gastroenterol Res Pract. 2018;2018:9250757.
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–5712.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
   PubMed Web of Science ®Google Scholar
• Graf W, Cashin PH, Ghanipour L, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27(1):293–300.
   PubMed Web of Science ®Google Scholar
• Korphaisarn K, Kopetz S. BRAF-directed therapy in metastatic colorectal cancer. Cancer J. 2016;22(3):175–178.
   PubMed Web of Science ®Google Scholar
• Jesinghaus M, Konukiewitz B, Foersch S, et al. Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Mod Pathol. 2018;31(5):829–839.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. Gastroenterology. 2019;158:291–302.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shi YL, Zhou K, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9(7):739.
   PubMed Web of Science ®Google Scholar
• Taggart MW, Abraham SC, Overman MJ, et al. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015;139(6):782–790.
   PubMed Web of Science ®Google Scholar
• van Velthuysen M-LF, van Eeden S, Carr NJ. The enigma of goblet cell tumors of the appendix. Am J Surg Pathol. 2019;24(3):98–104.
   Google Scholar
• Burke AP, Sobin LH, Federspiel BH, et al. Goblet cell carcinoids and related tumors of the vermiform appendix. Am J Clin Pathol. 1990;94(1):27–35.
   PubMed Web of Science ®Google Scholar
• Nonaka D, Papaxoinis G, Lamarca A, et al. A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related adenocarcinoma). Hum Pathol. 2018;72:18–27.
   PubMed Web of Science ®Google Scholar
• Isaacson P. Crypt cell carcinoma of the appendix (so-called adenocarcinoid tumor). Am J Surg Pathol. 1981;5(3):213–224.
   PubMed Web of Science ®Google Scholar
• Gui X, Meng Z, McConnell YJ, et al. Differing expression profiles of Notch/enterocyte and Wnt/secretory lineage signallings are associated with morphological diversity of appendiceal tumours. J Clin Pathol. 2017;70(1):40–50.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Classification of Tumours of the Digestive System. WHO Classification of Tumours. 4th ed. Vol. 3. Edited by Bosman FT, Carneiro F, Hruban RH, Theise ND. 2010. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Digestive-System-2010
   Google Scholar
• Hristov AC, Young RH, Vang R, et al. Ovarian metastases of appendiceal tumors with goblet cell carcinoidlike and signet ring cell patterns: a report of 30 cases. Am J Surg Pathol. 2007;31(10):1502–1511.
   PubMed Web of Science ®Google Scholar
• Anderson NH, Somerville JE, Johnston CF, et al. Appendiceal goblet cell carcinoids: a clinicopathological and immunohistochemical study. Histopathology. 1991;18(1):61–65.
   PubMed Web of Science ®Google Scholar
• Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–1443.
   PubMed Web of Science ®Google Scholar
• Wen KW, Grenert JP, Joseph NM, et al. Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. Hum Pathol. 2018;77:166–174.
   PubMed Web of Science ®Google Scholar
• Stancu M, Wu TT, Wallace C, et al. Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol. 2003;16(12):1189–1198.
   PubMed Web of Science ®Google Scholar
• Clift AK, Frilling A. Neuroendocrine, goblet cell and mixed adeno-neuroendocrine tumours of the appendix: updates, clinical applications and the future. Exp Rev Gastroenterol Hepatol. 2017;11(3):237–247.
   PubMed Web of Science ®Google Scholar
• Brathwaite SA, Smith SM, Wai L, et al. Mixed adenoneuroendocrine carcinoma: a review of pathologic characteristics. Hum Pathol. 2018;73:184–191.
   PubMed Web of Science ®Google Scholar
• Jesinghaus M, Konukiewitz B, Keller G, et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017;30(4):610–619.
   PubMed Web of Science ®Google Scholar
• Li XL, Zhou J, Chen ZR, et al. P53 mutations in colorectal cancer – molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015;21(1):84–93.
   PubMed Web of Science ®Google Scholar
• Ramnani DM, Wistuba II, Behrens C, et al. ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer. 1999;86(1):14–21.
   PubMed Web of Science ®Google Scholar
• Desouki MM, Lioyd J, Xu H, et al. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary. Hum Pathol. 2013;44(11):2536–2541.
   PubMed Web of Science ®Google Scholar
• Jaffee IM, Rahmani M, Singhal MG, et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med. 2006;130(10):1522–1526.
   PubMed Web of Science ®Google Scholar
• Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. 2005;123(3):394–404.
   PubMed Web of Science ®Google Scholar
• Alsaad KO, Serra S, Perren A, et al. CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix. Int J Surg Pathol. 2007;15(3):252–257.
   PubMed Web of Science ®Google Scholar